39 results
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
26 Mar 24
Results of Operations and Financial Condition
7:42am
into the first half of 2027.
3 Research and Development (R&D) Expenses. R&D expenses in 2023 were $42.3 million, compared to $32.4 million in 2022 … and per share data)
6 2023 2022 Operating expenses Research and development 42,318$ 32,361$ General and administrative 18,820 12,876 Total operating
8-K
EX-99.1
jluyfv43incs1h0391
1 Feb 24
Departure of Directors or Certain Officers
7:16am
8-K
EX-99.1
t6zrart19 osrz
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.1
1o85 zanc7g
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
424B5
090qut
20 Jul 23
Prospectus supplement for primary offering
4:11pm
424B5
jlu984k4rv2lku
17 Jul 23
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
wl6ro24snf29sh6xm
9 May 23
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
7:08am
PRE 14A
6b5ax o1lqv
14 Apr 23
Preliminary proxy
4:33pm
8-K
EX-99.1
yb411np x48n
14 Nov 22
Acumen Pharmaceuticals Reports Third Quarter 2022
4:10pm
8-K
EX-99.1
hvxoji cxw6u
15 Aug 22
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
4:36pm